Ethic Inc. Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ethic Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.7% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 42,002 shares of the medical research company’s stock after buying an additional 5,066 shares during the quarter. Thermo Fisher Scientific comprises about 0.4% of Ethic Inc.’s holdings, making the stock its 29th largest position. Ethic Inc.’s holdings in Thermo Fisher Scientific were worth $21,851,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Farallon Capital Management LLC raised its holdings in Thermo Fisher Scientific by 73.8% during the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company’s stock worth $641,577,000 after purchasing an additional 523,800 shares in the last quarter. First Manhattan CO. LLC. raised its position in Thermo Fisher Scientific by 0.6% in the fourth quarter. First Manhattan CO. LLC. now owns 891,321 shares of the medical research company’s stock worth $464,010,000 after acquiring an additional 4,991 shares in the last quarter. Clark Capital Management Group Inc. boosted its position in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company’s stock worth $2,312,000 after purchasing an additional 23 shares in the last quarter. Deutsche Bank AG boosted its holdings in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock worth $687,553,000 after buying an additional 114,277 shares in the last quarter. Finally, Colonial Trust Co SC grew its position in Thermo Fisher Scientific by 3.5% during the fourth quarter. Colonial Trust Co SC now owns 1,550 shares of the medical research company’s stock worth $806,000 after buying an additional 53 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of several research analyst reports. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Citigroup dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $607.43.

Thermo Fisher Scientific Trading Up 0.7 %

NYSE:TMO opened at $410.54 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a market capitalization of $154.97 billion, a P/E ratio of 24.84, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12-month low of $402.81 and a 12-month high of $627.88. The business has a 50 day simple moving average of $466.94 and a 200 day simple moving average of $516.54.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. During the same period last year, the firm posted $5.11 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.